Branched chain amino acids

The branched-chain amino acids, or BCAAs, are leucine, isoleucine and valine, the three protein amino acids whose aliphatic side chains are branched [1]. Animals cannot make them, yet they are abundant in animal tissues: they make up about 35% of the essential amino acids in most mammals and about 18% of the amino acids in proteins [2].

The three are eaten together and broken down by the same enzymes, so they are usually studied as one group, although their effects in the body differ [2]. They are also widely sold as sports supplements [3]. When the European Food Safety Authority assessed the health claims made for them, it found that none had been established [1].

Skeletal formulas of L-leucine, L-isoleucine and L-valine, each with a branched hydrocarbon side chain
The three branched-chain amino acids: L-leucine, L-isoleucine and L-valine.
Branched-chain amino acids at a glance
MembersLeucine, isoleucine, valine
Made in the bodyNo (essential) [2]
Share of essential amino acids in mammalsAbout 35% [2]
Adult requirement (WHO)Leucine 39, isoleucine 20, valine 26 mg/kg a day [4]

Chemical structure of the branched-chain amino acids

Each of the three has a hydrocarbon side chain with a single methyl branch. Valine has five carbon atoms (C5H11NO2). Leucine and isoleucine both have six and the same formula, C6H13NO2; they are constitutional isomers that differ only in where the methyl branch sits: on the fourth carbon in leucine and on the third in isoleucine [5].

LeucineIsoleucineValine
FormulaC6H13NO2C6H13NO2C5H11NO2
Molar mass, g/mol [6]131.17131.17117.15
Isoelectric point [6]5.986.025.96
Solubility in water, 25 °C, g/kg [6]23.834.288
Hydropathy index (Kyte–Doolittle) [7]3.84.54.2
Stereocentres121

Their side chains are small and water-repelling. Isoleucine, valine and leucine are the three most hydrophobic amino acids on the Kyte–Doolittle scale [7], and together the BCAAs account for about 63% of the hydrophobic amino acids in proteins [2]. For the same reason they are among the less soluble amino acids. Their solubility depends on pH and is lowest near the isoelectric point [5].

Isomers of the branched-chain amino acids

Like other amino acids, the BCAAs used in proteins are the L-forms. Isoleucine has a second stereocentre in its side chain, at the β-carbon, so it can exist as four stereoisomers. Only L-isoleucine, with the (2S,3S) configuration, is built into proteins. Its (2S,3R) diastereomer, L-alloisoleucine, is found only in minute amounts in the blood of healthy people [5]. In maple syrup urine disease it rises, and it is the most sensitive and specific marker for diagnosis [8].

Norleucine and norvaline are the straight-chain isomers of leucine and valine. They are not normally used in proteins, but Escherichia coli can make them as by-products of its BCAA pathway and build them by mistake into recombinant proteins, a problem for the pharmaceutical industry [5].

Skeletal formulas of L-alloisoleucine, L-norleucine and L-norvaline
L-Alloisoleucine, the (2S,3R) diastereomer of L-isoleucine (left), and the straight-chain isomers L-norleucine (centre) and L-norvaline (right). None of them is a normal building block of proteins.

The close similarity of the three makes them hard to measure. They lack groups that absorb ultraviolet light, so they were long measured after reaction with a reagent such as ninhydrin. Leucine and isoleucine have exactly the same mass, so ordinary mass spectrometry of protein fragments cannot tell them apart; special fragmentation methods are needed. Today liquid chromatography with mass spectrometry can separate leucine, isoleucine and alloisoleucine without derivatisation [5].

How branched-chain amino acids are made industrially

Bacteria, plants and fungi make the BCAAs; animals do not. Because the pathway is missing in animals, its enzymes are targets for herbicides, antimicrobial and antifungal agents [2]. In microbes valine and isoleucine are made by the same enzymes: valine from pyruvate, isoleucine from 2-ketobutyrate, which is formed from threonine. Leucine is built from the last intermediate of the valine pathway, and the final step for all three is the transfer of an amino group from glutamate [5].

A 2024 review by two scientists at Merck Life Science describes how BCAAs are produced. The main industrial method is fermentation, chiefly with the bacterium Corynebacterium glutamicum, which is also used to make lysine and glutamate; E. coli is used as well. Because the BCAAs switch off their own synthesis by feedback inhibition, producers use strains whose key enzymes have been made resistant to it. Hydrolysis of proteins such as soy protein supplies only a small share. Separating the three from one another is a major challenge. It relies on their different solubilities: in one patented process leucine crystallises first at pH 1 to 2, isoleucine follows on cooling with hydrochloric acid, and valine is recovered from the remaining liquid. Copper or nickel complexes and ion-exchange chromatography are also used [5].

Metabolism of branched-chain amino acids

All three are broken down by the same first two steps [2]:

  1. A branched-chain aminotransferase (BCAT) removes the amino group, usually passing it to α-ketoglutarate to form glutamate, and leaves a branched-chain keto acid. This step is reversible. One form of the enzyme, BCAT2, is found in the mitochondria of almost all tissues; the other, BCAT1, is mainly in the brain.
  2. The branched-chain keto acid dehydrogenase complex (BCKDH) then removes the carboxyl group as carbon dioxide. This step is irreversible and commits the amino acid to breakdown.

BCKDH is switched off when a kinase, BCKDK, phosphorylates it, and switched on again by the phosphatase PPM1K [5]. After these two steps the pathways part. Leucine ends as acetyl-CoA and acetoacetate, so it is ketogenic; valine ends as succinyl-CoA, which can be used to make glucose; isoleucine gives both acetyl-CoA and succinyl-CoA [5]. Only valine yields 3-hydroxyisobutyrate (3-HIB), which can leave the cell and is found in plasma [2]; its possible role in insulin resistance is described on the valine page.

What sets the BCAAs apart is where they are broken down. The enzymes that break down the other essential amino acids are largely confined to the liver, but those for the BCAAs are found throughout the body [2]. The liver has little BCAT activity, so most BCAAs from a meal pass through it unchanged and reach other tissues; the keto acids formed in muscle are taken up by the liver and oxidised there [5]. In tracer studies in mice every tissue examined oxidised BCAAs, and skeletal muscle oxidised more than any other [2].

After a protein-rich meal the level of BCAAs in the blood rises two- to threefold and returns to baseline within three hours. In the fasting state the blood contains about 200 µmol/l of valine, 100 µmol/l of leucine and 60 µmol/l of isoleucine [2].

Maple syrup urine disease

Maple syrup urine disease is an inherited deficiency of BCKDH. It was first described in the 1950s. Without the complex, the BCAAs, their keto acids and alloisoleucine build up in the blood, and the urine takes on the smell that gives the disease its name, caused by a rare breakdown product, sotolone [2]. In the classic form, levels rise within 12 to 24 hours of birth, and without treatment brain swelling and coma follow by the seventh to tenth day. It is rare in most populations, with an estimated incidence of about 1 in 185,000 live births [8].

Treatment is a diet low in leucine, using formulas free of BCAAs, with measured supplements of isoleucine and valine [8]. A liver transplant cures the disease, which shows that about 10% of the body’s normal BCKDH activity is enough; the removed liver of a patient can in turn be given to someone else, because the recipient’s other tissues supply enough of the enzyme [2].

BCAAs and insulin resistance

People with obesity and insulin resistance have higher blood levels of BCAAs, an observation first made in the 1960s [2]. In the Framingham Offspring Study, Wang and colleagues measured amino acids in blood samples from people without diabetes and followed them for 12 years. Isoleucine, leucine, valine, tyrosine and phenylalanine were all associated with future diabetes, and people in the top quarter of a score combining isoleucine, phenylalanine and tyrosine had a five- to sevenfold higher risk [9].

Whether the BCAAs help cause insulin resistance or are only a sign of it is still debated [5]. Neinast and colleagues list evidence for a causal role: genetic variants near the gene for the phosphatase that activates BCKDH both raise BCAA levels and raise the risk of insulin resistance, and BCAAs infused into healthy adults impair the uptake of glucose. They add that insulin resistance itself probably raises BCAA levels, so the two may reinforce each other, and that nearly all studies of the mechanism have been done in rodents [2].

BCAA supplements

Do BCAAs build muscle?

BCAA supplements are sold mainly on the claim that they stimulate muscle growth. In a 2017 review, Wolfe found no studies in humans in which muscle protein synthesis had been measured after BCAAs alone were taken by mouth. In the only two studies of BCAAs alone, in which they were infused into a vein, both synthesis and breakdown of muscle protein fell, and breakdown still exceeded synthesis [3]. He argued that this is what theory predicts: muscle cannot make new protein from three essential amino acids when the other six can come only from the breakdown of muscle itself. The situation differs when BCAAs are added to protein: in one study 5 g of BCAAs added to 6.25 g of whey protein stimulated muscle protein synthesis about as much as 25 g of whey [3]. Wolfe has received research grants or honoraria from food companies and a beef industry programme and owns shares in Essential Blends, LLC [3].

Taking one BCAA alone can lower the others. A high intake of leucine activates the pathway that breaks down all three, so the blood levels of valine and isoleucine fall [3].

The European assessment of BCAA health claims

In 2010 the EFSA panel on nutrition assessed claims that BCAAs help build or maintain muscle, limit the loss of muscle power at high altitude, speed recovery from muscle fatigue, improve mental performance after exercise, make exercise feel easier and support the immune system. For each claim it concluded that a cause-and-effect relationship had not been established. Many of the references submitted did not measure the claimed outcome. The two studies on muscle mass, with 22 and 9 participants, gave the BCAA group more protein than the control group. The studies on mental performance and perceived exertion compared BCAA drinks with placebo drinks that contained less energy [1]. The panel noted that a claim for protein and muscle mass had already been accepted, and found no effect of BCAAs over and above that of protein [1].

Muscle soreness after exercise

The best-studied use is recovery from exercise that damages muscle. A 2024 meta-analysis by Salem and colleagues pooled 18 randomised trials with 331 healthy, active participants, in 14 of which only men took part, that compared BCAAs alone with a placebo. Muscle soreness was lower with BCAAs from 24 to 96 hours after exercise. Creatine kinase, an enzyme released from damaged muscle, was lower immediately after exercise and at 72 hours but not at 24, 48 or 96 hours, and another marker, lactate dehydrogenase, did not change [10]. The results for soreness varied widely between studies, and there were signs of publication bias at some time points. The authors also noted that most trials did not record how much protein the participants ate, so it is unclear whether the supplement did more than make up their daily intake [10]. The review had no funding and the authors declared no competing interests [10].

Liver disease

The clearest medical use is in liver disease. Hepatic encephalopathy is a disturbance of brain function caused by liver failure. A Cochrane review updated in 2026 pooled 18 randomised trials with 934 adults, almost all with cirrhosis. BCAAs reduced hepatic encephalopathy (risk ratio 0.79), but the authors rated the certainty of this evidence as low, and the effect on mortality was very uncertain. Nausea and diarrhoea occurred in 12% of people given BCAAs and 3% of those in control groups, but this evidence too was very uncertain [11]. The review received no funding; three of its authors had run trials included in it and did not assess their own trials [11].

This section summarises research. It is not medical advice.

Food sources of branched-chain amino acids

All food proteins contain the three BCAAs. In the analysis of protein isolates by Gorissen and colleagues, the three together made up 15.9 g per 100 g of whey protein, 14.6 g of caseinate, 13.5 g of milk protein and of potato protein, 12.6 g of corn protein and 11.1 g of casein. Pea and brown rice proteins contained 10.7 and 10.6 g, wheat 9.3 g and soy 9.1 g, and the lowest amounts were in lupin (6.1 g) and hemp (4.9 g). Human muscle contained 14.0 g (sums calculated from the published table) [12]. These figures are per 100 g of powder, and the protein content of the isolates differed, from 51% in egg protein to 86% in caseinate [12].

The WHO/FAO/UNU expert consultation set the adult requirement for leucine at 39 mg per kilogram of body weight a day. It had too little tracer data to measure isoleucine and valine directly, so it derived them from leucine in proportion to their content in body protein, giving 20 mg/kg for isoleucine and 26 mg/kg for valine. Studies that measured the total requirement for the three together gave higher figures, from 110 to 134 mg/kg a day [4]. Typical intakes are well above these levels: Neinast and colleagues estimate that an average American man eats about 145 mg/kg of leucine, 88 mg/kg of valine and 66 mg/kg of isoleucine a day [2].

In short

  • The branched-chain amino acids are leucine, isoleucine and valine, essential amino acids with branched hydrophobic side chains.
  • Leucine and isoleucine have the same formula and mass; isoleucine has a second stereocentre, and its diastereomer alloisoleucine marks maple syrup urine disease.
  • They are made industrially by bacterial fermentation, and separating the three from one another is difficult.
  • Unlike other essential amino acids, they are broken down mainly outside the liver, above all in muscle.
  • High blood levels are linked with insulin resistance, but cause and effect are still debated.
  • EFSA found no established benefit for any claimed effect; trials suggest less muscle soreness after damaging exercise, and BCAAs may reduce hepatic encephalopathy in cirrhosis.

References

  1. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to branched-chain amino acids (BCAA) and growth or maintenance of muscle mass (ID 442, 444, 445, 447, 448, 451, 1478), attenuation of the decline in muscle power following exercise at high altitude (ID 443), faster recovery from muscle fatigue after exercise (ID 447, 448, 684, 1478), improvement of cognitive function after exercise (ID 446), reduction in perceived exertion during exercise (ID 450) and “healthy immune system” (ID 449) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 8(10):1790 (2010). https://doi.org/10.2903/j.efsa.2010.1790
  2. Neinast M, Murashige D, Arany Z. Branched Chain Amino Acids. Annual Review of Physiology 81:139–164 (2019). https://doi.org/10.1146/annurev-physiol-020518-114455
  3. Wolfe RR. Branched-chain amino acids and muscle protein synthesis in humans: myth or reality? Journal of the International Society of Sports Nutrition 14:30 (2017). https://doi.org/10.1186/s12970-017-0184-9
  4. Joint WHO/FAO/UNU Expert Consultation. Protein and amino acid requirements in human nutrition. WHO Technical Report Series 935. Geneva: World Health Organization (2007).
  5. Reifenberg P, Zimmer A. Branched-chain amino acids: physico-chemical properties, industrial synthesis and role in signaling, metabolism and energy production. Amino Acids 56:51 (2024). https://doi.org/10.1007/s00726-024-03417-2
  6. Haynes WM, Lide DR, Bruno TJ, editors. Properties of amino acids. In: CRC Handbook of Chemistry and Physics, 97th edition, pp. 7-1–7-2. Boca Raton: CRC Press (2016).
  7. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology 157(1):105–132 (1982). https://doi.org/10.1016/0022-2836(82)90515-0
  8. Strauss KA, Puffenberger EG, Carson VJ. Maple Syrup Urine Disease. In: Adam MP, et al., editors. GeneReviews. Seattle: University of Washington (2006, updated 23 April 2020). https://www.ncbi.nlm.nih.gov/books/NBK1319/
  9. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nature Medicine 17(4):448–453 (2011). https://doi.org/10.1038/nm.2307
  10. Salem A, Ben Maaoui K, Jahrami H, AlMarzooqi MA, Boukhris O, Messai B, Clark CCT, Glenn JM, Ghazzaoui HA, Bragazzi NL, Ammar A, Trabelsi K, Chtourou H. Attenuating muscle damage biomarkers and muscle soreness after an exercise-induced muscle damage with branched-chain amino acid (BCAA) supplementation: a systematic review and meta-analysis with meta-regression. Sports Medicine – Open 10:42 (2024). https://doi.org/10.1186/s40798-024-00686-9
  11. Aamann L, Deshpande N, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, Vilstrup H, Gluud LL. Branched-chain amino acids for people with cirrhosis and hepatic encephalopathy. Cochrane Database of Systematic Reviews 2026, Issue 1, Art. No. CD001939. https://doi.org/10.1002/14651858.CD001939.pub5
  12. Gorissen SHM, Crombag JJR, Senden JMG, Waterval WAH, Bierau J, Verdijk LB, van Loon LJC. Protein content and amino acid composition of commercially available plant-based protein isolates. Amino Acids 50(12):1685–1695 (2018). https://doi.org/10.1007/s00726-018-2640-5